Zucator 100 Tablet contains Remogliflozin Etabonate 100 mg, an oral antihyperglycemic agent belonging to the class of sodium-glucose co-transporter 2 (SGLT2) inhibitors. It is indicated for the management of type 2 diabetes mellitus, either as monotherapy or in combination with other antidiabetic agents, to improve glycemic control. Remogliflozin Etabonate acts by inhibiting SGLT2 in the proximal renal tubules, reducing glucose reabsorption and promoting urinary glucose excretion, thereby lowering blood glucose levels independently of insulin secretion. This mechanism also contributes to modest weight reduction and blood pressure improvement. Zucator 100 is administered orally, typically once daily, with or without food, as prescribed by a healthcare professional. It is contraindicated in patients with type 1 diabetes, diabetic ketoacidosis, severe renal impairment, or hypersensitivity to the active substance. Common adverse effects may include urinary tract infections, genital mycotic infections, and increased urination. Patients should be monitored for signs of volume depletion, renal function changes, and electrolyte imbalances during therapy. Zucator 100 should be used cautiously in patients with a history of bladder cancer or recurrent urinary tract infections. Regular monitoring of glycemic parameters and renal function is recommended to optimize therapeutic outcomes and ensure patient safety.